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Abstract
Aims
We aimed to investigate predictive factors for visual and anatomic outcomes in patients with
macular edema secondary to non-infectious uveitis.
Material and methods
We conducted a multicenter, prospective, observational, 12-month follow-up study. Partici-
pants included in the study were adults with non-infectious uveitic macular edema (UME),
defined as central subfoveal thickness (CST) of >300 μm as measured by spectral domain
optical coherence tomography (SD-OCT) and fluid in the macula. Demographic, clinical and
tomographic data was recorded at baseline, 1, 3, 6 and 12 months. Foveal-centered SD-
OCT exploration was set as the gold-standard determination of UME using a standard Mac-
ular Cube 512x128 A-scan, within a 6 x 6 mm2 area, and the Enhanced High Definition Sin-
gle-Line Raster. To assess favorable prognosis, the main outcomes analyzed were the
best-corrected visual acuity (BCVA) and the CST. Favorable prognosis was defined as sus-
tained improvement of BCVA (2 lines of gain of the Snellen scale) and CST (decrease of
20% of the initial value or <300 μm) within a 12 month period.
Results
Fifty-six eyes were analyzed. The number of eyes with sustained improvement in the CST
was 48 (86.2%), against 23 (41.1%) eyes with sustained improvement in BCVA. Favorable
prognosis, as defined above, was observed in 18 (32.1%) eyes. UME prognosis was nega-
tively correlated with baseline foveal thickening, alteration in the vitreo-macular interface
and cystoid macular edema. In contrast, bilaterally, systemic disease and the presence of
anterior chamber cells were predictive of favorable prognosis.
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Conclusion
Available treatment modalities in UME may avoid chronic UME and improve anatomic out-
come. However, the proportion of functional amelioration observed during 12 months of fol-
low-up is lower. Thicker CST, alteration in the vitreo-macular interface and cystoid macular
edema may denote less favorable prognosis. Conversely, bilaterally, systemic disease and
anterior chamber cells may be associated with favorable prognosis in UME.
Introduction
Macular edema (ME) is the main cause of visual impairment and the most frequent structural
ocular complication in patients with uveitis [1–3].
Uveitic macular edema (UME) may persist and lead to visual acuity (VA) loss even with
adequate control of uveitis activity [4–5].
Currently the specific mechanisms that contribute to the pathogenesis of inflammatory ME
are not well defined. It remains unclear why some patients have a single episode, whereas oth-
ers develop recurrent or chronic UME [6].
The initial factors involved in UME include toxic effects on the retinal vessels and retinal
pigment epithelium, inflammatory mediators in the eye and mechanical tractions. There is
therefore a breakdown of the blood-retinal barrier and ME develops when the leakage of fluid
across the retina vessel wall and through retinal pigment epithelium accumulates within the
macular area [7].
Previously ME was assessed by measuring the area of macular leakage with fluorescein angi-
ography (FA) [8]. More recently however, optical coherence tomography (OCT) has been
engineered to perform similar functions as FA by measuring retinal thickness [9–10]. OCT
has now replaced FA for controlling ME, in part because VA is associated more with retinal
thickness than with macular leakage [9–10].
New local and systemic therapies, such as intravitreal dexamethasone slow-release implants
and biologic drugs, have been approved for treatment of uveitis in recent years. Information
about the functional effect of these therapies and the anatomical location of their action how-
ever remains unclear.
Little data exists regarding the factors influencing sustained anatomic and visual recovery
in eyes with UME, whilst most of studies performed are still retrospective. To attempt to gauge
this gap in current knowledge we performed a prospective study with uveitis to determine if
demographic, clinical features, as well as specific OCT findings, could predict a favorable prog-
nosis in eyes with UME.
Material and methods
Study design
We performed a multicenter, prospective, observational, 12-month follow-up study.
All patients with UME in at least one eye were proposed for inclusion. Three referral cen-
ters for ocular inflammatory diseases in Spain (Hospital Clinic of Barcelona, Hospital Cruces
and Hospital Clı´nico San Carlos) participated in the recruitment of patients from January
2015 to January 2017.
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Inclusion and exclusion criteria
Adult patients with non-infectious uveitis who presented with ME in at least one eye were
included if the following criteria were met: 1) BCVA of 20/60 or less but greater than 20/200 2)
CST of>300 μm as measured by SD-OCT (Cirrus, Carl Zeiss Meditec, Dublin, CA) and fluid
in the macula. Exclusion criteria were limited to infectious uveitis, unclear media (confidenti-
ality analysis<5), concomitant ocular diseases that compromise visual prognosis indepen-
dently of ME, pregnancy, immunocompromising systemic diseases (including, but not limited
to AIDS, leukemia, lymphoma, chemotherapy etc.) and eyes with any intervention (surgery,
intravitreal therapy) in the previous 4 months.
Only one eye from each study participant was enrolled. Whenever bilateral UME was pre-
sented and both eyes met inclusion criteria, the eye with the thickest UME was selected. The
Standardization of Uveitis Nomenclature Working Group criteria was used to anatomically
classify the uveitis[11].
Ethics statement
Ethical and legal restrictions did apply according to the IRB statement on the project’s
approval (current Spanish law on Data Protection: Organic Law 15/1999). Local ethics com-
mittees approved the study (Comite´ e´tico de Investigacio´n Clı´nica del Hospital Clı´nic de Bar-
celona 2013/8574; Comite´ de e´tica de la investigacio´n con medicamentos de Euskadi, Hospital
Universitario Cruces PI201406; Comite´ e´tico de investigacio´n clı´nica del Hospital Clı´nico San
Carlos de Madrid 13/ 244-E). All patients provided written informed consent, and the research
followed the regulations of the Declaration of Helsinki.
Ophthalmologic assessment
The following mandatory protocol-based assessments were performed and were reported in
the present study: at baseline, and at 1, 3, 6 and 12 months. Other visits at different time-points
were allowed, at the discretion of the treating physician.
These visits were conducted at each clinical site by the investigators and data was recorded
in an electronic case report form designed ad hoc. Ancillary tests were ordered at the investiga-
tor discretion.
During each appointment, a complete eye examination was carried out, including best cor-
rected visual acuity (BCVA), slit lamp examination, Goldman applanation tonometry, indirect
fundus examination under pupil dilation and SD-OCT. BCVA was performed with Snellen charts
in decimal scale at a test distance of 6 m. Results on BCVA were converted to logarithm of the
minimum angle of resolution for statistical analysis. Inflammatory activity, that is the presence or
absence of anterior chamber cells, vitreous haze or posterior segment inflammatory signs as
judged by the investigator, was recorded at each visit. Other imaging methods, e.g., FA, were
optional and were left to the discretion of the researcher. Although FA was not included as proto-
col-based assessment in our study, it was indicated specifically to evaluate physiologic macular
leakage and uveitis (e.g., for suspected vasculitis, neovascularization, optic nerve leakage. . .).
At each visit a standardized questionnaire about past and current ophthalmic events and
treatments was recorded. Treatments were divided into local (peri/intraocular injection of tri-
amcinolone or intravitreal dexamethasone implant), systemic (oral corticosteroids, immuno-
suppressive or biologic drugs) or a combination of both. Although there are no guidelines for
the treatment of UME, it was recommended to treat UME until a resolution, if there was no
contraindication. The decision on the treatment for local and/or systemic therapy was influ-
enced by the severity of the inflammation and the UME, and by uni- or bilaterally of the uveitis
and UME. Our first concern in the treatment of UME was to diminish inflammatory activity
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and maintain or improve BCVA. Even eyes with long-standing ME with structural changes
and macular atrophy were treated as needed in order to achieve ME disappearance. Eyes could
receive more than one injection for their UME if the investigator determined it to be medically
necessary. Eyes with no BCVA improvement or those with no CST reduction after intravitreal
corticosteroids were considered non-responding to the treatment and could be not retreated
at the investigator’s discretion. Pars plana vitrectomy was limited to remove inflammatory
mediators in the vitreous and vitreo-macular traction/epiretinal membrane.
SD-OCT
All subjects underwent SD-OCT exploration as gold-standard determination of UME using
Macular cube 512x128 A-scan, within a 6 x 6 mm2 area centered on the fovea; and the
Enhanced High Definition Single-Line Raster, which collected data along a 6 mm horizontal
line. Imaging assessment was performed by two masked investigators who were blind to clini-
cal data of the corresponding patients. In the event of discrepancies, the two graders made the
assessment together and reached a consensus. Masked investigators were asked to determine
the presence of UME and the qualitative and quantitative SD-OCT findings.
The Macular cube 512x128 A-scan was used to assess the pattern of UME (sub-retinal fluid,
cystoid, diffuse or tractional ME), the CST, the macular volume and the diameter of the great-
est cyst if present. Foveal thickness between the Bruch’s membrane and the inner limiting
membrane within the central Early Treatment Diabetic Retinopathy Study subfield (foveal
thickness within 500 μm of the foveal center) defined CST. Macular edema was defined as CST
of> 300 μm as measured by SD-OCT and fluid in the macula. Any cystic space was considered
cystoid macular edema (CME) if ME met the above mentioned definition. The Enhanced
High Definition Single-Line Raster scan was used to assess the disruption of the ellipsoid line,
the vitreo-macular interface (VMI), the sub-retinal fluid (SRF) and the subfoveal choroidal
thickness. Subfoveal choroidal thickness was measured at the fovea from the posterior edge of
the retinal pigment epithelium to the choroid/sclera junction.
Outcome measures
The main outcome measures analyzed were BCVA and CST. Sustained visual improvement
was defined as 2 lines of maintained gain of the Snellen BCVA (-0.2 base 10 logarithm of
BCVA decimal fraction–equivalent or a more favorable change in BCVA) at 12 months of fol-
low-up. Otherwise, improvement of CST was defined as a maintained decrease of 20% of the
baseline value or reduction to less than 300 μm at 12 months of follow-up. To define favorable
prognosis of eyes with UME, we focused on eyes with improvement in BCVA and CST, as per
the above mentioned definitions, who presented sustainment of both outcome measures
within a 12 month period. Conversely, eyes with non-favorable prognosis were those who did
not improve both outcomes at 12 months of follow-up.
Statistical analysis
To describe the qualitative variables, absolute frequencies and percentages were used. The
description of quantitative variables was performed using the mean and standard deviation
(SD). The Kolmogorov-Smirnov test was used to assess the normality of distributions.
In the case of quantitative variables, the comparison of the characteristics of the eyes
depending on the presence of favorable prognosis, BCVA and CST, was carried out using the
Student t-test (or Mann-Whitney U-test if normality was not assumed). The Chi-squared test
(Fisher test for frequencies <5) was used for the comparison of categorical variables. Wilcoxon
Test was performed in order to analyze changes in the main outcomes.
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A final model was developed using back stepwise logistic regression analysis including
favorable prognosis as the dependent variable. Variables with a significance <0.1 in the univar-
iate analysis were included as independent variables. The results have been described with
odds ratio (OR) with a 95% confidence interval (CI) and p-values. The Hosmer-Lemeshow
goodness-of-fit test was performed to assess the overall fit of the model [12]. The combination
of predictors from the final models was used to calculate the probabilities of favorable progno-
sis. The probability of favorable prognosis in this population was calculated by the following
formula: Exp (b) / (1 + Exp (b)), where b = -2.933 + 2.100 (in the case of laterality) + 2.367 (in
the case of anterior chamber cells). Finally, Receiver Operating Characteristic curve analysis
was used to assess the predictive power to the favorable prognosis. For all the tests p-values <
0.05 were considered statistically significant. The statistical package R Studio (version 2.5) was
used for the statistical analyses.
Results
Baseline characteristics and outcomes
Fifty-six eyes from fifty-six patients with UME were included in the study. The mean age of
patients was 51 years (range 21–89 years) and the male-to-female ratio was 3:4. Most patients
were Caucasian (n = 54). The mean time from the first episode of UME to baseline was 18.3
months (range 0–144 months). From analyzing anatomic sites of inflammation, posterior uve-
itis was the predominant anatomical diagnosis (n = 20, 36% of eyes); 15 (26%) eyes presented
with anterior uveitis, 12 (22%) with panuveitis and 9 (16%) with intermediate uveitis. The
most frequent systemic disorders associated with uveitis were seronegative spondyloarthropa-
thies, Vogt-Koyanagi-Harada syndrome and sarcoidosis, whereas Birdshot chorioretinopathy
was the main ocular syndrome. Macular edema occurred in unclassified uveitis in 13 (23.2%)
eyes (Table 1).
Mean BCVA (LogMAR) improved from 0.45 at baseline to 0.33 at 1 month follow-up
(p<0.001), and reached the maximum at 3 months (0.24, p<0.001).
Mean CST at baseline was 437.83 μm, but decreased significantly after 1 month to
357.39 μm (p<0.001), followed by a mean sustained improvement, reaching 329.65 μm at 12
months (p<0.001) (Table 2).
In our cohort, after 12 months of follow-up, the number of eyes with sustained improve-
ment of CST was 48 (86.2%), against 23 (41.1%) eyes with sustained visual improvement.
However, favorable prognosis, as sustained improvement of both CST and BCVA, was
observed in 18 (32.1%) eyes. There was no significant association with favorable prognosis of
UME and demographic items including gender and age (p>0.05).
Clinical factors associated with favorable prognosis
The anatomic pattern of uveitis increased the likelihood of sustained visual improvement, in
eyes with only anterior uveitis more readily experiencing sustained gains in vision than those
with intermediate, posterior, or panuveitis (p<0.05). CST improvement however did not vary
significantly across the anatomic classifications (p = 0.999).
In relation to whether the disease was only ocular or systemic, a higher favorable prognosis
was observed in the group with systemic disease (p = 0.004).
No significant association was found between chronic UME and the prognosis. In our
cohort, none of the initial treatment modalities, either local, systemic, or a combination of
both, were associated with favorable prognosis regarding the short-term and final functional
and anatomic outcome (p = 0.273). In relation to whether the UME was unilateral or bilateral,
there was a significant difference in cases with bilateral UME since these cases showed
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favorable prognosis (OR: 3.07; CI 95% 0.96–9.83; p = 0.049). The presence of cells in the ante-
rior chamber at any degree was associated with favorable prognosis (OR: 4.46; CI 95% 1.31–
15.16; p = 0.017). No significant association was found between anterior chamber cells and/or
vitreous haze and persistent macular edema (p = 0.123). No relationship was found between
the prognosis and the clinical variables of cataract (p = 0.928), keratic precipitates (p = 0.595),
vitreous haze (p = 0.256) or chorioretinitis (p = 0.546).
Table 1. Baseline characteristics at the time of UME diagnosis.
Baseline Characteristics Eyes, n (%)
Age (years, mean, range) 51 (21–89)
Gender
Male 24 (42.9)
Female 32 (57.1)
Race
Caucasian 54 (97)
Not Caucasian 2 (3)
Time from first UME episode to baseline (months, mean, range) 18.34 (0–144)
Chronic UME
UME not chronic (�6 months) 32 (57.1)
UME chronic (>6 months) 24 (42.9)
Primary uveitis diagnosis
Unilateral 35 (62.5)
Bilateral 21 (37.5)
Etiological diagnosis
Ocular 19 (34)
Systemic 24 (42.8)
Not classified 13 (23.2)
Anatomical diagnosis
Anterior 15 (26)
Intermediate 9 (16)
Posterior 20 (36)
Panuveitis 12 (22)
Treatment
Topical (only) 2 (3.6)
Local (only) 14 (25.5)
TC (peri/intraocular)
Dexamethasone implant
5
9
Systemic ± topical/local 38 (67.3)
Oral Corticosteroids
Immunosupressive drugs
Biologic drugs
35
19
13
Pars plana vitrectomy 2 (3.6)
Patterns of UME
CME 43 (76.8)
DRT 12 (21.4)
SRF 21 (38)
Tractional 16 (25)
Abbreviations: UME, uveitic macular edema; TC, triamcinolone; CME, cystoid macular edema; DRT, diffuse retinal
thickening; SRF, sub-retinal fluid
https://doi.org/10.1371/journal.pone.0210799.t001
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In the multivariate analysis, the anterior chamber cells (OR: 10.66; CI 95% 2.01–14.50,
P = 0.005) and the bilaterally (OR: 8.17, CI 95% 1.57–22.57; p = 0.012) were independently
related to favorable prognosis. A probability model including these two independent clinical
variables showed that the probability of favorable prognosis increased with the number of
putative predictors. The probability for favorable prognosis without any of these characteristics
would therefore be 5.1%, overcoming 82.3% for those having both variables (Table 3).
The final model was calibrated with p values of 0.920 by using the Hosmer-Lemeshow test.
The capacity of the significant variables derived from the logistic regression model to predict
favorable prognosis was evaluated through Receiver Operating Characteristic curve with an
area under the curve of 0.760 (CI 95% 0.630–0.900; p<0.001).
Influence of OCT parameters on favorable prognosis
When the eyes were analyzed according to the type of UME, CME was reported in 43 (76.8%)
eyes, SRF noted in 21 (38%) eyes, alteration in the VMI in 16 (25%) and diffuse retinal thicken-
ing (DRT) in 12 (21.4%) of the eyes with uveitis (Table 1). It was observed that CME was a pre-
dictive factor of less favorable prognosis. Also noted, the bigger the cyst was, the less favorable
the prognosis was found to be. No significant difference was observed between other patterns
of OCT, as DRT or SRF patterns were not found to be predictors of favorable prognosis in our
cohort (p = 0.427 and p = 0.732 respectively). Conversely, the presence of alteration in the
VMI was associated with less sustained visual and CST improvement throughout the follow-
up (OR: 9.23; CI 95% 1.35–35.28; p = 0.026). Eyes without alteration of the VMI showed a sig-
nificantly higher sustained visual improvement (p = 0.016).
Table 2. Mean values of the principal outcome measures: BCVA and CST in 56 eyes with UME at baseline and throughout different time-points of follow-up.
Outcomes Baseline Month 1 Month 3 Month 6 Month 12
BCVA (LogMAR, SD) 0.45 (0.36) 0.33 (0.31) 0.24 (0.25) 0.26 (0.3) 0.3 (0.32)
Change from baseline (LogMAR, SD) 0.13 (0.23) 0.2 (0.28) 0.19 (0.26) 0.14 (0.31)
P-value� <0.001 <0.001 <0.001 <0.001
P-value�� <0.001 0.038 0.357 0.216
CST
(μm, SD)
437.83 (122.22) 357.39 (118.89) 341.79 (107.9) 337.73 (135.48) 329.65
(108.13)
Change from baseline
(μm, SD)
-82.56 (143.71) -83.1 (131.71) -89.22 (153.8) -96.44
(154.02)
p-value� <0.001 <0.001 <0.001 <0.001
p-value�� 0.012 0.396 0.477
Abbreviations: BCVA, best corrected visual acuity; CST, central subfoveal thickness; UME, uveitic macular edema; SD, standard deviation
� Baseline; Wilcoxon Test.
�� Previous time-points; Wilcoxon Test.
https://doi.org/10.1371/journal.pone.0210799.t002
Table 3. Probability of favorable prognosis including bilaterally and anterior chamber cells in UME.
% Laterality Anterior chamber cells
5.1 Unilateral Absent
30.3 Bilateral Absent
36.2 Unilateral Present
82.3 Bilateral Present
Abbreviations: UME, uveitic macular edema
https://doi.org/10.1371/journal.pone.0210799.t003
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Eyes with alteration in the ellipsoid layer at baseline had significantly higher sustained
improvement of the CST during the follow-up (p = 0.016), though no association was found
between the BCVA and the ellipsoid layer at baseline and throughout the follow-up
(p = 0.135).
Finally, no significant association was observed between macular volume measures and
favorable prognosis (OR: 0.80); CI 95% 0.57–1.12; p = 0.193) nor between choroidal thickness
values and favorable prognosis (p = 0.223).
Discussion
There is a clear gap in scientific literature investigating the long-term prognosis and the effi-
cacy of several treatment modalities and little is known about clinical and structural findings
that can influence UME response. This present study provides data on the functional and ana-
tomical status of eyes with UME during 12 months of follow-up, investigating clinical and
tomographic variables influencing patient outcome, regardless of the therapeutic approach
used.
Interestingly, results revealed that the proportion of improvement in BCVA and CST
obtained in our cohort peaked at 3 months, potentially suggesting that a substantial number of
eyes with UME present an important visual recovery upon receiving attention. Three months
after receiving treatment it seemed that VA and CST were similar to the vision and the CST
maintained throughout the follow-up period.
In our study, in order to determine the prognosis of UME, the sustainment of the improve-
ment of BCVA and CST was taken into account as a whole. If VA and CST were analyzed sepa-
rately, it was observed that the rate of sustained improvement was higher for CST. High values
of CST at baseline negatively affected the final visual and anatomic prognosis, but no relation
was found between the value of the initial VA and the final prognosis. This finding can be
explained by other factors that could influence VA at baseline, such as outer retina integrity,
macular perfusion, etc. Our study is in agreement with other authors who reported a negative
correlation between foveal thickness and VA in ME [13–14]. The CST calculation is therefore
important for a functional prognostic assessment; however, in our experience, the macular vol-
ume seems less valuable than the CST because it correlates with BCVA with no significant dif-
ference. Other recent publications using SD-OCT in diabetic ME also showed a correlation
between the total macular volume and VA without significant difference [15–16].
Neither gender nor age were found to significantly alter the course of visual improvement.
With respect to age, we could not find differences in sustained visual or CST improvement
comparing younger (<40 years), middle age (40–60 years) and older patients (�60 years). Pre-
vious studies have shown that incidences in visual improvement do not vary significantly
across age and gender in patients with uveitis [17–19], though Tranos et al. did report less
visual improvement among elderly patients with uveitis [17]. It has been postulated that the
gradual decrement of retinal cell function of aged individuals could be associated with the
breakdown of the blood-retinal barrier and the inadequate ability to pump out the fluid
through the retinal pigment epithelium [17, 20].
The favorable prognosis was also influenced by the anatomical type of the uveitis since an
anterior location of inflammation may reflect a greater chance of sustained visual recovery;
intermediate, posterior and panuveitis were predictive of a lesser incidence of sustained visual
improvement. Conversely, sustained improvement in the CST was not associated with the ana-
tomical type of uveitis. From analyzing anatomic sites of inflammation, posterior uveitis was
the predominant anatomical diagnosis in our cohort, followed by anterior uveitis, panuveitis,
and intermediate uveitis. Specific uveitis entities linked to the common development of UME
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included Birdshot chorioretinopathy and seronegative spondyloarthropathies, however 23.2%
of our cohort with UME was of undetermined etiology. Interestingly, uveitis forms that are
not limited to ocular involvement had a more favorable prognosis.
The therapeutical approach to inflammatory ME differs according to its laterality: in unilat-
eral ME, local treatment modalities are preferred, while the use of systemic immunomodula-
tory drugs might be necessary in bilateral cases [21–22]. In our patient population, bilateral
UME was associated with more favorable prognosis, however we did not find differences in
the treatment modality used. This is partly because uveitis encompasses a heterogeneous
group of inflammatory pathologies and frequently the treatment of UME involves the use of
multiple therapeutic strategies over time.
Several clinical findings, if present during follow-up, accurately predicted sustained visual
improvement, such as the presence of anterior chamber cells. Better control of anterior cham-
ber cells was associated with higher sustained visual and CST improvement. Although the
study was not designed to evaluate the various treatment strategies for ME, the benefit associ-
ated with control of inflammation suggests that treatments which successfully control inflam-
mation are also beneficial for ME [19]. This could also explain why systemic and bilateral
forms present a favorable prognosis maintained over time. The fact that most of these forms of
uveitis have received systemic treatments may explain the long-term control of the inflamma-
tion since these treatments last much longer than the local modalities that require multiple
injections. We recognize however the number of eyes included in the analysis limits the accu-
racy of an estimate and more studies are needed.
Another important finding of this study is the association between the integrity of the VMI
with the macular thickness and the visual prognosis. Previous studies of alteration in the VMI
and UME have also described the detrimental clinical effects of the epiretinal membrane for-
mation as well as a higher risk of treatment failure for UME [23–24].
Our data also suggested that bigger cyst diameter in the CME pattern correlated with the
prognosis, since larger sizes of the cysts were associated with less favorable prognosis. Cyst size
therefore may be of value as a correlating morphological parameter with central retinal func-
tion and visual recovery [25]. Analysis of the current series did not find any other association
in other patterns of UME. Lehpamer et al. reported that although SFR on OCT was associated
with greater CST and worse VA at baseline, it was associated with good respond to treatment
and with favorable prognosis [26]. Although previously published data comparing UME with
and without SRF has shown an association of SRF with favorable prognosis [27], we have not
found a significant association. This was likely because of the small sample of eyes with SRF
included. We cannot comment on the prevalence of patterns of ME in specific forms of uveitis,
because the number of cases from each specific form in our cohort of cases was too small.
The strengths of the study included the prospective design, use of standardized masked
data collection protocols, a centralized masked reading center for the evaluation of OCT
images, and recruitment from multiple uveitis referral centers. The primary limitation of this
study was the number of eyes included in the analysis, which limits the precision of the
estimates.
To our knowledge, this is the first prospective study that takes into account not only an ana-
tomical improvement outcome but also a functional outcome to predict favorable prognosis of
UME. The main reason for carrying out this study approach is our experience in the clinical
practice where we have observed eyes with reduction in macular thickness without improving
VA. These findings are not surprising as VA depends on diverse factors including media opac-
ities, macular atrophy, macular ischemia, as well as permanent structural anomalies. For this
reason, we designed a study to analyze both variables in order to predict which factors could
positively influence eyes which developed well in both VA and CST.
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In conclusion, our cohort of cases with UME presenting to tertiary uveitis centers lead to a
reasonably favorable prognosis for sustained visual and anatomic improvement over time. Sev-
eral eye-specific factors, if present at baseline, predicted favorable prognosis. Bilateral presenta-
tion of UME, systemic involvement, and cases with active anterior chamber cells, tended to
show sustained improvement and favorable prognosis. In contrast, thicker CST, altered VMI
or big dimension of the cystic spaces predicted less favorable visual prognosis.
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